OKYO Pharma CMO buys 20,000 shares at $1.40 each

OKYO Pharma Limited (NASDAQ: OKYO) announced that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on the Nasdaq at $1.40 per share, according to a press release statement.

OKYO Pharma is a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and anterior segment eye diseases. The company has said it plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain.

You May Also Be Interested In

• OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
• Manulife names Sarah Chapman as global marketing chief
• Citi Trends CFO steps down, search for successor underway